Cancers, Vol. 12, Pages 1295: Adenovirus and Immunotherapy: Advancing Cancer Treatment by Combination

Cancers, Vol. 12, Pages 1295: Adenovirus and Immunotherapy: Advancing Cancer Treatment by Combination Cancers doi: 10.3390/cancers12051295 Authors: Mizuho Sato-Dahlman Christopher J. LaRocca Chikako Yanagiba Masato Yamamoto Gene therapy with viral vectors has significantly advanced in the past few decades, with adenovirus being one of the most commonly employed vectors for cancer gene therapy. Adenovirus vectors can be divided into 2 groups: (1) replication-deficient viruses; and (2) replication-competent, oncolytic (OVs) viruses. Replication-deficient adenoviruses have been explored as vaccine carriers and gene therapy vectors. Oncolytic adenoviruses are designed to selectively target, replicate, and directly destroy cancer cells. Additionally, virus-mediated cell lysis releases tumor antigens and induces local inflammation (e.g., immunogenic cell death), which contributes significantly to the reversal of local immune suppression and development of antitumor immune responses (“cold” tumor into “hot” tumor). There is a growing body of evidence suggesting that the host immune response may provide a critical boost for the efficacy of oncolytic virotherapy. Additionally, genetic engineering of oncolytic viruses allows local expression of immune therapeutics, thereby reducing related toxicities. Therefore, the combination of oncolytic virus and immunotherapy is an attractive therapeutic strategy for cancer trea...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Review Source Type: research